By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and
By Udhayvir Singh Grewal, MD, Assistant Professor of Medical Oncology, Emory University School of Medicine Guest Contributor The Annual NANETS Multi-Disciplinary Symposium 2025 was a
Congratulations to Dr. Dawn Quelle, NETRF Board of Scientific Advisors co-chair, and the team at the University of Iowa Health, for winning a $10.7 million
NETRF CEO Elyse Gellerman, Chief Scientific Officer Anna Greene, and Director of Patient Education Jessica Thomas joined hundreds of neuroendocrine cancer specialists and patient advocates
A recent review published in the Journal of Oncology Practice explores how patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) view the use and timing of radioligand
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) in partnership with NETRF is proud to announce Dr. Carolin Kitzberger of TUM
The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging agent may deliver clearer and more comprehensive scans for people
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and
Updated on October 31, 2025 Early clinical trial results show that AlphaMedix™ (212Pb-DOTAMTATE), an investigational targeted alpha therapy, achieved all of its main goals and
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to transforming the future of neuroendocrine cancer care. As the world’s leading funder of neuroendocrine